Modulight Biotherapeutics Secures $12 Million to Advance Optogenetic Treatments for Neurological Diseases Modulight Biotherapeutics has concluded a successful $12.2 million Seed funding round, aimed at enhancing its cutting-edge optogenetic technology for treating neurological disorders.

Modulight Biotherapeutics Secures $12 Million to Advance Optogenetic Treatments for Neurological Diseases #United_States #Boston #Neurological_Disorders #Optogenetics #Modulight

Ge Shi is our next ASP reporter! See what she has to say about this study of the use of liquid metal nanoparticles in photodynamic cancer therapy below!

onlinelibrary.wiley.com/doi/10.1111/...

#modulight